Diabetic Kidney Disease: Finerenone, Nonsteroidal MRAs, and the FIDELIO/FIGARO Evidence
Finerenone: Mechanism and Rationale
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that differs structurally from spironolactone and eplerenone. Unlike steroidal MRAs, finerenone has no active metabolites, equal distribution between heart and kidney tissue, and a more favorable hyperkalemia profile. It blocks aldosterone-mediated inflammation and fibrosis in the kidney and cardiovascular system, targeting pathways complementary to ACE inhibitors/ARBs and SGLT2 inhibitors. The nonsteroidal structure eliminates the gynecomastia and sexual side effects associated with spironolactone.
FIDELIO-DKD: Renal Outcomes
FIDELIO-DKD enrolled 5,734 patients with type 2 diabetes and CKD (eGFR 25-75 mL/min with UACR 30-5000 mg/g) already receiving maximally tolerated RAS blockade. Finerenone (10-20 mg daily) reduced the primary renal composite (kidney failure, sustained ≥40% eGFR decline, renal death) by 18% (HR 0.82, 95% CI 0.73-0.93, p=0.001). The key secondary cardiovascular composite (CV death, nonfatal MI, nonfatal stroke, HF hospitalization) was reduced by 14% (HR 0.86, 95% CI 0.75-0.99). The UACR reduction was approximately 31% at month 4, serving as an early indicator of treatment response.
FIGARO-DKD: Cardiovascular Outcomes
FIGARO-DKD enrolled a broader DKD population (5,325 patients, eGFR ≥25 with UACR 30-5000 mg/g, including earlier-stage CKD) and achieved its primary cardiovascular endpoint: 13% reduction in the composite of CV death, nonfatal MI, nonfatal stroke, and HF hospitalization (HR 0.87, 95% CI 0.76-0.98, p=0.03). The benefit was driven predominantly by a 29% reduction in heart failure hospitalization (HR 0.71, 95% CI 0.56-0.90). The pooled FIDELITY analysis (13,026 patients) confirmed consistent cardiorenal benefit across the DKD spectrum.
Sponsored
Practical Implementation: Dosing and Potassium Management
Finerenone is initiated at 10 mg daily if eGFR is 25-60 mL/min, or 20 mg daily if eGFR is ≥60 mL/min, provided serum potassium is ≤4.8 mEq/L. Potassium monitoring is required at 4 weeks, then periodically. In FIDELIO, hyperkalemia led to permanent discontinuation in 2.3% of finerenone patients versus 0.9% placebo, with hospitalization for hyperkalemia in 1.4% versus 0.3%. Dietary potassium counseling, avoidance of concurrent potassium supplements, and dose reduction (20 mg to 10 mg) or temporary hold if potassium exceeds 5.5 mEq/L are essential management strategies.
The Multi-Pillar DKD Strategy: Combining Therapies
The 2024 KDIGO guidelines recommend a multi-pillar approach for DKD: maximally tolerated ACE inhibitor or ARB (pillar 1), SGLT2 inhibitor (pillar 2), finerenone (pillar 3), and GLP-1 receptor agonist (pillar 4 for patients with T2D needing additional glycemic control or weight management). In FIDELIO-DKD, only 4.6% of patients were on background SGLT2 inhibitor therapy, so real-world experience combining finerenone with dapagliflozin or empagliflozin is emerging. Early data suggest the combination is well-tolerated with a manageable hyperkalemia risk, as SGLT2 inhibitors have a modest potassium-lowering effect that may offset finerenone-induced hyperkalemia. Target HbA1c, blood pressure (<130/80 mmHg), and UACR should be reassessed iteratively as each pillar is added.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.